Related Experiment Video
Updated: Aug 13, 2026
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Percutaneous brachytherapy for small-sized non-small cell lung cancer
F Imamura1, M Chatani, T Nakayama
1Department of Pulmonary Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
Lung Cancer (Amsterdam, Netherlands)
|August 25, 1999
Summary
High dose rate brachytherapy offers a novel treatment for inoperable lung adenocarcinoma. This minimally invasive approach successfully shrank a small tumor without significant side effects, showing promise for select patients.
Area of Science:
- Oncology
- Radiation Oncology
- Pulmonary Medicine
Background:
- Lung adenocarcinoma presents treatment challenges, particularly in patients with comorbidities making them inoperable.
- Percutaneous high dose rate (HDR) interstitial brachytherapy is an emerging technique for localized tumor ablation.
Observation:
- A patient with a 12-mm lingular pulmonary adenocarcinoma, deemed inoperable due to emphysema and pleural adhesion, was treated with HDR brachytherapy.
- The procedure involved percutaneous insertion of an iridium-192 (192Ir) source via a fine applicator needle for targeted irradiation.
Findings:
- The tumor received a single fraction of irradiation, with the target volume within the 40 Gy iso-dose line.
- Calculated doses at 12.5 mm from the tumor center ranged from 19.2 to 32.2 Gy (mean 24.8 Gy).
- No immediate complications such as pneumothorax or hemoptysis were observed.
Implications:
- Successful tumor shrinkage and sustained absence of growth for 2 years suggest HDR brachytherapy's efficacy as a standalone treatment for select early-stage lung cancers.
- This technique provides a potentially curative option for inoperable patients, improving outcomes and quality of life.
- Further research into HDR brachytherapy for pulmonary malignancies could expand treatment paradigms for non-small cell lung cancer.
